MX2019006742A - Preparacion farmaceutica y metodo para su fabricacion. - Google Patents

Preparacion farmaceutica y metodo para su fabricacion.

Info

Publication number
MX2019006742A
MX2019006742A MX2019006742A MX2019006742A MX2019006742A MX 2019006742 A MX2019006742 A MX 2019006742A MX 2019006742 A MX2019006742 A MX 2019006742A MX 2019006742 A MX2019006742 A MX 2019006742A MX 2019006742 A MX2019006742 A MX 2019006742A
Authority
MX
Mexico
Prior art keywords
layer
matrix material
preparation
pharmaceutical
composition
Prior art date
Application number
MX2019006742A
Other languages
English (en)
Inventor
Kanikanti Venkata-Rangarao
Billian Patrick
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of MX2019006742A publication Critical patent/MX2019006742A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Una preparación farmacéutica sólida. La presente invención se refiere a una preparación (10) farmacéutica que comprende una primera composición farmacéutica que tiene un material de matriz e ingredientes farmacéuticamente activos que se distribuyen en el material de matriz, en la que la primera composición farmacéutica comprende Praziquantel, Pirantel y Febantel como ingredientes farmacéuticos activos, en la que la preparación (10) comprende una segunda composición farmacéutica que tiene un material de matriz y al menos una de avermectinas y milbemicinas tal como Moxidectina como ingrediente farmacéuticamente activo que se distribuye en el material de matriz, en la que la preparación (10) se proporciona en una estructura de múltiples capas de manera tal que la primera composición se proporciona en una primera capa (12) y la segunda composición se proporciona en una segunda capa (14), en la que la primera capa (12) y la segunda capa (14) se separa mediante una capa (16) barrera que se proporciona entre la primera capa (12) y la segunda capa (14).
MX2019006742A 2016-12-09 2017-11-30 Preparacion farmaceutica y metodo para su fabricacion. MX2019006742A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16203308 2016-12-09
PCT/EP2017/081049 WO2018104150A1 (en) 2016-12-09 2017-11-30 Pharmaceutical preparation and method for its manufacture

Publications (1)

Publication Number Publication Date
MX2019006742A true MX2019006742A (es) 2019-09-05

Family

ID=57544274

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006742A MX2019006742A (es) 2016-12-09 2017-11-30 Preparacion farmaceutica y metodo para su fabricacion.

Country Status (16)

Country Link
US (1) US11382865B2 (es)
EP (1) EP3551173A1 (es)
JP (1) JP2020500898A (es)
KR (1) KR20190093571A (es)
CN (1) CN110022862B (es)
AU (1) AU2017370975A1 (es)
BR (1) BR112019011502A2 (es)
CA (1) CA3046275A1 (es)
CL (1) CL2019001555A1 (es)
CO (1) CO2019005955A2 (es)
DO (1) DOP2019000157A (es)
IL (1) IL266938A (es)
MX (1) MX2019006742A (es)
PH (1) PH12019501249A1 (es)
RU (1) RU2764849C2 (es)
WO (1) WO2018104150A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3114704A1 (en) * 2018-10-12 2020-04-16 Hovione Scientia Macrocyclic lactone formulations, methods of their preparation and use of the formulations in treating pathologies secondary to ophthalmic parasites

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4999226A (en) 1988-06-01 1991-03-12 Merrell Dow Pharmaceuticals Inc. Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination
US5030622A (en) 1989-06-02 1991-07-09 Merck & Co., Inc. Avermectin derivatives
IT1264517B1 (it) 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
DE60118132T2 (de) 2000-10-10 2006-10-19 Wyeth Anthelmintika
US6893652B2 (en) * 2001-08-27 2005-05-17 Wyeth Endoparasiticidal gel composition
IN191024B (es) 2001-09-25 2003-09-13 J B Chemicals And Pharmaceutic
US20040151759A1 (en) * 2002-08-16 2004-08-05 Douglas Cleverly Non-animal product containing veterinary formulations
TWI366442B (en) * 2003-07-30 2012-06-21 Novartis Ag Palatable ductile chewable veterinary composition
US7396819B2 (en) * 2003-08-08 2008-07-08 Virbac Corporation Anthelmintic formulations
WO2005084688A1 (fr) * 2004-03-04 2005-09-15 Yuwan Wang Poudre injectable contenant un vermifuge
US20060024368A1 (en) 2004-07-30 2006-02-02 Reza Fassihi Compressed composite delivery system for release-rate modulation of bioactives
US20060067954A1 (en) 2004-09-24 2006-03-30 Cottrell Ian W Lipid stabilized formulations
US7348027B2 (en) 2005-04-08 2008-03-25 Bayer Healthcare Llc Taste masked veterinary formulation
WO2008134819A1 (en) * 2007-05-07 2008-11-13 Jurox Pty Ltd Improved dosage form and process
US20080293645A1 (en) 2007-05-25 2008-11-27 Schneider Lawrence F Antiparasitic combination and method for treating domestic animals
EP3351546B1 (en) 2011-12-02 2024-02-14 Boehringer Ingelheim Vetmedica GmbH Long-acting injectable moxidectin formulations
HU231017B1 (hu) * 2012-05-08 2019-11-28 LAVET Gyógyszeripari Kft. Praziquantel tartalmú ízfedett formulációk
RU2693005C2 (ru) 2012-12-19 2019-07-01 Байер Энимэл Хельс ГмбХ Таблетки с улучшенным приёмом и хорошей устойчивостью при хранении
WO2015071668A1 (en) 2013-11-14 2015-05-21 Cipla Limited Pharmaceutical compositions
WO2018065826A1 (en) * 2016-10-06 2018-04-12 Sucampo Ag Multilayer beads for pharmaceutical use

Also Published As

Publication number Publication date
JP2020500898A (ja) 2020-01-16
BR112019011502A2 (pt) 2019-11-05
KR20190093571A (ko) 2019-08-09
CN110022862A (zh) 2019-07-16
RU2764849C2 (ru) 2022-01-21
EP3551173A1 (en) 2019-10-16
CN110022862B (zh) 2022-05-24
CL2019001555A1 (es) 2019-10-25
RU2019121235A3 (es) 2021-02-16
IL266938A (en) 2019-07-31
US20200069591A1 (en) 2020-03-05
RU2019121235A (ru) 2021-01-12
US11382865B2 (en) 2022-07-12
WO2018104150A1 (en) 2018-06-14
DOP2019000157A (es) 2019-07-15
CA3046275A1 (en) 2018-06-14
CO2019005955A2 (es) 2019-06-19
AU2017370975A1 (en) 2019-05-30
PH12019501249A1 (en) 2019-12-02

Similar Documents

Publication Publication Date Title
BRPI0513909A (pt) comprimido farmacêutico de camada múltipla para a liberação controlada de ingredientes ativos com solubilidade altamente dependente do ph
WO2008146178A3 (en) A novel tablet dosage form
BR112012001353B8 (pt) anel vaginal, e, método para fabricar um anel vaginal
WO2018152320A8 (en) Systems and methods for the fabrication of tablets, including pharmaceutical tablets
PH12018550210A1 (en) Oral dosage form with drug composition, barrier layer and drug layer
PH12020550806A1 (en) Core tablet composite preparation comprising mosapride and rabeprazole
NO20082047L (no) Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme
EP3954380A4 (en) SELF-EMULSIFYING FLAVONOID-POLYPHENOL MEDICINAL COMPOSITION, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION AND ITS USE
WO2019194773A3 (en) The combination comprising linagliptin and metformin
PH12019501249A1 (en) Pharmaceutical preparation and method for its manufacture
WO2019240699A3 (en) Tablet formulations comprising metformin and sitagliptin processed with hot-melt extrusion
WO2020013777A3 (en) Tablet formulations comprising metformin and sitagliptin
AR097202A1 (es) Composiciones farmacéuticas de ranolazina y dronedarona, procedimiento para elaborar tableta bicapa
MX2022007707A (es) Comprimidos de edoxaban.
BR112018013408A2 (pt) derivados de c-glicosídeo que têm anel fenila fusionado ou sais farmaceuticamente aceitáveis dos mesmos, método para preparar os mesmos e composição farmacêutica compreendendo os mesmos
CL2022003477A1 (es) Compuesto de alquenilpirimidina, método de preparación del mismo y aplicación del mismo
PH12014501601A1 (en) Artemisinin-based combination therapy for treating viral mediated disease
AU2017265377A1 (en) Tetrahydropyran and Thiopyran derivatives having multimodal activity against pain
BR112021024026A2 (pt) Método para a produção de uma forma de dosagem farmacêutica sólida ou semissólida, forma de dosagem farmacêutica sólida ou semissólida e forma de dosagem sólida ou semissólida
MX2017004242A (es) Prueba de disolucion de ingredientes activos farmaceuticos hidrofobicos tal como avermectinas con o sin pirantel.
WO2020190900A8 (en) Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof
EP3792253A4 (en) COMPOUND OF NOVEL STRUCTURE, COMPLEX, PHARMACEUTICAL COMPOSITION ANTI-CANCER AND ANTI-CANCER DRUG CONTAINING THEM
EP3898596A4 (en) PHARMACEUTICAL COMPOUND, METHOD FOR MAKING IT AND ITS USE AS A THERAPEUTIC AGENT
EP3903800A4 (en) <SMALLCAPS/>? ? ?ARTEMISIA? ? ? ? METHODS FOR OBTAINING ENRICHED FRACTIONS OF GENUS ACTIVE SUBSTANCES, ENRICHED FRACTIONS AND BIOACTIVE COMPOSITION
PH12018501392A1 (en) Pharmaceutical composite preparation